Allianz Asset Management
CLDX icon

Allianz Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Allianz Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-36,205
Closed -$1.23M – 2278
2022
Q1 		$1.23M Hold
36,205
– – ﹤0.01% 1769
2021
Q4 		$1.4M Buy
36,205
+26,369
+268% +$1.15M ﹤0.01% 1757
2021
Q3 		$531K Sell
9,836
-96,077
-91% -$4.51M ﹤0.01% 2220
2021
Q2 		$3.54M Buy
105,913
+21,345
+25% +$586K ﹤0.01% 1257
2021
Q1 		$1.74M Buy
84,568
+10,068
+14% +$231K ﹤0.01% 1455
2020
Q4 		$1.3M Buy
+74,500
New +$1.34M ﹤0.01% 1425
2018
Q2 		– Sell
-891
Closed -$31K – 2627
2018
Q1 		$31K Buy
+891
New +$34.5K ﹤0.01% 2610
2016
Q1 		– Sell
-20,560
Closed -$4.86M – 2496
2015
Q4 		$4.86M Buy
+20,560
New +$4.48M 0.01% 1361
2013
Q3 		– Sell
-9,107
Closed -$2.13M – 1780
2013
Q2 		$2.13M Buy
+9,107
New +$1.79M ﹤0.01% 1192

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Allianz Asset Management's CLDX Position: Q2 2022 in Review

Allianz Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 36,205 shares — an estimated $1.23M sold.

Allianz Asset Management first reported a position in CLDX in Q2 2013 and held it in 9 quarters. The position peaked at $4.86M in Q4 2015. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

  • Allianz Asset Management reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Allianz Asset Management sold 36,205 Celldex Therapeutics shares in Q2 2022, an estimated $1.23M.
  • Allianz Asset Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 9 quarters.
  • Allianz Asset Management's Celldex Therapeutics position peaked at $4.86M in Q4 2015.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on Allianz Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.